$INCY · INCYTE CORP
Incyte filed its Q3 2026 10-Q, reporting a net loss of $784.8M ($3.86/share) on total revenues of $1.557B (+14% YoY). The loss was driven by R&D expense of $1.79B, more than triple the $506.6M in Q3 2025. For the nine months, net income was $104.1M ($0.50 diluted EPS) on revenues of $4.50B, with operating cash flow of $201.7M.
- Q3 net loss of $784.8M vs. net income of $424.2M in Q3 2025, driven by R&D expense surging to $1.79B from $506.6M
- GAAP EPS of $(3.86) vs. $2.11 diluted EPS in the year-ago quarter
- Total revenues rose 14% YoY to $1.557B, with OPZELURA net sales up 36% to $254.9M
- Nine-month operating cash flow collapsed to $201.7M from $870.2M in the prior-year period
- Cash and equivalents remain strong at $3.28B with no debt drawn
Extended-hours trading shows INCY at $117.99, up +1.02% vs. the regular close of $116.80, suggesting the market had already priced in the R&D-driven loss and is focusing on the 14% revenue growth and strong cash position.
A profitable biotech swinging to a $784.8M quarterly loss on a 3.5x R&D surge is a dramatic capital-allocation signal that demands investor scrutiny of the pipeline return prospects.
The massive R&D ramp — from $507M to $1.79B in a single quarter — is atypical for a commercial-stage biotech of Incyte's size and signals an aggressive pipeline bet that peers like AbbVie or Bristol Myers would typically spread over multiple years.
R&D expense tripled YoY to $1.79B in Q3 alone, with no guarantee of pipeline returns; the filing notes the OPZELURA Medicaid settlement contributed $246M to nine-month sales, a non-recurring benefit. Operating cash flow fell 77% YoY.